Abbott expands access to Precision Oncology portfolio through integration with Flatiron's OncoEMR® platform

Abbott (NYSE: ABT) and Flatiron Health integrated Abbott's Precision Oncology portfolio into Flatiron's OncoEMR on March 30, 2026.

Rhea-AI Summary

Abbott (NYSE: ABT) and Flatiron Health integrated Abbott's Precision Oncology portfolio into Flatiron's OncoEMR on March 30, 2026. The integration lets clinicians order Abbott tests and receive results inside the OncoEMR workflow, expanding access across Flatiron's network of 1,600+ community cancer centers and 4,700 providers.

This single, unified experience covers Oncotype DX Breast Recurrence Score®, OncoExTra®, Oncodetect®, and Riskguard®, aiming to reduce administrative burden and accelerate informed treatment decisions in community oncology settings.

Positive

• Network reach: expands access to Abbott tests across >1,600 community cancer centers
• Provider access: integrates with workflows used by 4,700 providers in Flatiron's North America network
• Portfolio unification: enables ordering and results for multiple tests (Oncotype DX, OncoExTra, Oncodetect, Riskguard) within OncoEMR

Negative

• None.

Argus Mar 30 session

-2.03% close to close Open Argus

Details

News Market Reaction – ABT

In the Mar 30 session, ABT declined 2.03%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement expands digital access to Abbott’s Precision Oncology portfolio by embedding test ...

Analysis

This announcement expands digital access to Abbott’s Precision Oncology portfolio by embedding test ordering and results into Flatiron’s OncoEMR® for more than 1,600 community cancer centers and 4,700 providers. It follows the Exact Sciences acquisition, which added core cancer screening assets. Together, these steps underscore a strategy to integrate diagnostics more tightly into oncology workflows. Investors may watch adoption across community practices, incremental volume trends in key tests, and how this integration supports the broader oncology growth narrative.

Key Figures

Community cancer centers: more than 1,600 centers Oncology providers: 4,700 providers Announcement date: March 30, 2026

Community cancer centers

more than 1,600 centers

Flatiron Health North America network coverage

Oncology providers

4,700 providers

Clinicians in Flatiron’s North America network

Announcement date

March 30, 2026

Integration of Abbott Precision Oncology with OncoEMR

Historical Context

5 past events · Latest: Mar 26

5 events

1. Mar 26

   Earnings call notice

   24h Move

   -0.3%

   Announcement of timing and access details for Q1 2026 earnings call.

2. Mar 24

   Awareness campaign

   24h Move

   -0.8%

   Cologuard-focused campaign with celebrity partners to boost screening uptake.

3. Mar 23

   Acquisition completion

   24h Move

   -0.6%

   Closing of Exact Sciences acquisition and addition of oncology portfolio.

4. Mar 20

   Acquisition update

   24h Move

   -1.6%

   Pre-close update on Exact deal, including projected 2026 sales and EPS impact.

5. Mar 12

   Clinical trial data

   24h Move

   -1.9%

   FreeDM2 trial showed improved HbA1c and time-in-range with Libre CGM.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

precision oncology, electronic medical record (emr)

2 terms

precision oncology medical

"Abbott's comprehensive Precision Oncology portfolio into OncoEMR®"

Precision oncology uses detailed biological information from a patient’s tumor—like genetic changes or specific markers—to choose treatments most likely to work for that individual, much like tailoring a suit to a person’s measurements instead of selling one-size-fits-all clothing. It matters to investors because these targeted approaches can improve treatment success, support premium pricing and companion diagnostic tests, and shorten development and approval timelines, creating focused markets with both higher potential returns and specialized risks.

electronic medical record (emr) technical

"OncoEMR®, Flatiron's cloud-based Electronic Medical Record (EMR) platform"

A digital system that healthcare providers use to store, organize and access patients’ clinical information—replacing paper charts with computerized records such as diagnoses, medications, test results and visit notes. Investors care because EMRs can change how efficiently clinics and hospitals operate, affect billing and regulatory compliance, and create recurring revenue or costs for vendors; think of an EMR as a digital filing cabinet that speeds care, data sharing and cash flow.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• Broadens access to Abbott's Precision Oncology tests across more than 1,600 community cancer care centers and 4,700 providers in Flatiron's North America network, helping accelerate informed treatment decisions
• Allows oncologists to order tests and view results directly in the clinical workflow

ABBOTT PARK, Ill. and NEW YORK, March 30, 2026 /PRNewswire/ -- Abbott (NYSE: ABT), the global healthcare company, and Flatiron Health, a leading healthtech company advancing point-of-care solutions in oncology, today announced the integration of Abbott's comprehensive Precision Oncology portfolio into OncoEMR^®, Flatiron's cloud-based Electronic Medical Record (EMR) platform.

Through this integration, oncology providers can now digitally order Abbott tests – individually or in combination – and receive status updates and results directly within their existing OncoEMR clinical workflow. Available Abbott tests include the Oncotype DX Breast Recurrence Score®, OncoExTra®, Oncodetect®, and Riskguard® tests, enabling clinicians to access the comprehensive portfolio through a single, unified experience. This approach supports more informed treatment decisions across multiple stages of cancer care while helping reduce administrative burden and keeping the focus on patient care.

The integration expands access to Abbott's Precision Oncology tests across Flatiron's national network of more than 1,600 community cancer care centers, where 4,700 providers deliver care and where most cancer care in the U.S. takes place.

"We're focused on making it easier for clinicians to access the right information at the right moment of care," said Quincy Weatherspoon, VP and GM of Point of Care Solutions, Flatiron Health. "By integrating Abbott's Precision Oncology portfolio directly into OncoEMR, we're reducing friction in the workflow and helping providers move faster – from test ordering to treatment decisions. This is what it looks like to bring more connected, data-driven care to the point of care."

"For community oncology practices, where most cancer care is delivered, this removes a key barrier to accessing our portfolio at the point of care, helping accelerate treatment decisions and enabling more informed, personalized patient care," said Brian Baranick, vice president, Precision Oncology, Abbott.

About Abbott
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 122,000 colleagues serve people in more than 160 countries. Connect with us at abbott.com and on LinkedIn,  Facebook, Instagram, X and YouTube.

About Flatiron
Flatiron Health is a healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer. Through machine learning and AI, real-world evidence, and breakthroughs in clinical trials, we continue to transform patients' real-life experiences into knowledge and create a more modern, connected oncology ecosystem. Flatiron Health is an independent affiliate of the Roche Group.

 

View original content:https://www.prnewswire.com/news-releases/abbott-expands-access-to-precision-oncology-portfolio-through-integration-with-flatirons-oncoemr-platform-302728101.html

SOURCE Abbott

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Abbott (ABT) announce on March 30, 2026 about OncoEMR integration?

Abbott announced integration of its Precision Oncology portfolio into Flatiron's OncoEMR to streamline test ordering. According to the company, clinicians can now order tests and receive status updates and results directly inside the OncoEMR clinical workflow.

How many centers and providers will have access to Abbott tests through the ABT and Flatiron deal?

The integration expands access across more than 1,600 community cancer centers and 4,700 providers. According to the company, that network represents Flatiron's North America footprint where much U.S. community cancer care is delivered.

Which Abbott Precision Oncology tests are available in OncoEMR for ABT investors and clinicians?

Available tests include Oncotype DX Breast Recurrence Score, OncoExTra, Oncodetect, and Riskguard. According to the company, these tests can be ordered individually or in combination via OncoEMR's unified experience.

How will the OncoEMR integration affect clinician workflow for Abbott tests (ABT)?

The integration reduces workflow friction by enabling digital ordering and in-platform results delivery inside OncoEMR. According to the company, this reduces administrative burden and helps speed from test order to treatment decisions.

Does the ABT and Flatiron integration change where Abbott Precision Oncology tests are performed?

No operational change to test processing was specified; the announcement focuses on digital ordering and results visibility inside OncoEMR. According to the company, the update primarily improves access and clinician workflow at point of care.

What is the investor relevance of Abbott's OncoEMR integration with Flatiron for ABT shareholders?

The integration potentially increases clinical access to Abbott's oncology tests across community practices, improving adoption opportunities. According to the company, this connectivity targets faster, more informed treatment decisions in community oncology settings.